NCT02756247 2022-10-10A Clinical Trial of Buparlisib and Ibrutinib in LymphomaMemorial Sloan Kettering Cancer CenterPhase 1 Completed37 enrolled
NCT02301364 2017-10-19Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)Memorial Sloan Kettering Cancer CenterPhase 2 Completed4 enrolled 11 charts